Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04119830
Title Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Roswell Park Cancer Institute
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Roswell Park Cancer Institute Buffalo New York 14263 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field